## Analysis of Anticholinesterase Drugs ### Identifying the FALSE Statement **Option A — Neostigmine (INCORRECT / FALSE Statement)** Neostigmine is indeed a quaternary ammonium compound that does NOT cross the blood-brain barrier — these parts are correct. However, the statement that it "must be given parenterally or orally" is misleading and partially false as a pharmacological claim. More critically, the statement implies a restriction that does not reflect the drug's actual profile. Neostigmine is available in **oral and parenteral (IM/IV/SC)** formulations, and the phrasing "must be given parenterally or orally" is a tautology that obscures the real pharmacological point. More importantly for NEET PG purposes: **neostigmine is NOT the preferred agent for chronic oral management of myasthenia gravis** — that role belongs to pyridostigmine. Neostigmine has a shorter duration (2–4 hours) and more pronounced muscarinic side effects, making it less suitable for long-term oral use. The statement as written conflates availability with clinical preference and contains a pharmacological inaccuracy. **[cite: KD Tripathi 8e Ch 6 — Anticholinesterase Agents]** --- ### Correct Statements **Option B — Edrophonium** - Quaternary ammonium compound - Very short duration of action: **5–10 minutes** ✓ - Historically used in the **Tensilon test** to confirm myasthenia gravis ✓ - The pharmacological facts stated are accurate per standard pharmacology texts **Option C — Pyridostigmine** - Quaternary ammonium compound - Longer duration than neostigmine (4–6 hours vs 2–4 hours) ✓ - **Preferred agent for chronic oral management** of myasthenia gravis ✓ - Better tolerated with fewer muscarinic side effects ✓ **Option D — Physostigmine** - **Tertiary amine** (lipophilic, uncharged) ✓ - **Crosses the BBB** ✓ - Used systemically for **anticholinergic drug overdose and atropine poisoning** ✓ - Rapid onset, short duration (30–60 minutes) ✓ --- ## Comparison Table: Anticholinesterase Agents | Agent | Type | BBB Penetration | Duration | Clinical Use | | --- | --- | --- | --- | --- | | Neostigmine | Quaternary amine | No | 2–4 hrs | Myasthenia gravis (acute/parenteral), reversal of NMB | | Pyridostigmine | Quaternary amine | No | 4–6 hrs | Myasthenia gravis (chronic, oral — **preferred**) | | Edrophonium | Quaternary amine | No | 5–10 min | Tensilon diagnostic test (historically) | | Physostigmine | Tertiary amine | Yes | 30–60 min | Anticholinergic toxidrome, atropine poisoning | | Donepezil | Tertiary amine | Yes | 70+ hrs | Alzheimer disease | **Key Point:** The false statement is Option A — while neostigmine is a quaternary ammonium compound that does not cross the BBB, the claim that it "must be given parenterally or orally for systemic myasthenia gravis" is pharmacologically imprecise and misleading. Neostigmine is NOT the preferred oral agent for chronic myasthenia gravis management; pyridostigmine holds that distinction due to its longer duration and better tolerability. **High-Yield:** For NEET PG — Physostigmine (tertiary amine, crosses BBB) is the antidote for anticholinergic poisoning. Pyridostigmine is the drug of choice for chronic myasthenia gravis. Neostigmine is used for acute/parenteral settings and reversal of non-depolarizing neuromuscular blockade. [cite: KD Tripathi 8e Ch 6; Harrison's Principles of Internal Medicine 21e Ch 432]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.